Intellia Therapeutics Inc Revenue per Employee (NTLA), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Intellia Therapeutics Inc   (NASDAQ: NTLA)
 

Intellia Therapeutics Inc 's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


Intellia Therapeutics Inc 's Revenue per employee fell on a trailing twelve month basis to $ 140,284, but the productivity of Intellia Therapeutics Inc 's employees remained above the company average.
Within the Healthcare sector Employees of 418 other companies have achieved higher revenue per employee. While Intellia Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 2381 to 3134. Intellia Therapeutics Inc has 377 employees.


What is Sales per Employee Ratio?






Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NTLA Revenue per Employee (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Revenue Change -48.03 % -46.23 % -9.5 % 78.79 % 51.27 %
Sales per Employee (TTM) $ 140,284 157,841 175,310 179,499 152,594
NTLA's Total Ranking # 3134 # 2381 # 2166 # 1231 #
Seq. Revenue Change -6.48 % -49.1 % -34.62 % 67.01 % -3.25 %

NTLA Company Profile >> Back to NTLA Efficiency Comparisons >> Compare NTLA Sales per Employee to its Competitors

Revenue per Employee Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 419
Overall Market # 3134

Revenue per Employee Statistics
High Average Low
$ 179,499 $ 114,305 $ 43,711
(Dec 31 2025)   (Dec 31 2016)



Financial Statements
Intellia Therapeutics Inc 's Revenue MRQ $ 7 Millions Visit NTLA's Income Statement
Intellia Therapeutics Inc 's Revenues TTM $ 53 Millions Visit NTLA's aggregate revenue growth
What are NTLA's Sales? Visit NTLA's Sales by Segment


  News about Intellia Therapeutics Inc Revenue per employee

Intellia Therapeutics Charts Ambitious Course for 2025: Prioritizing Late-Stage Programs and Strengthening Talent for CRISPR Innovation

Intellia Therapeutics Charts Ambitious Course for 2025: Prioritizing Late-Stage Programs and Strengthening Talent for CRISPR InnovationIn a bold move signaling its commitment to advancing groundbreaking gene editing technologies, Intellia Therapeutics, Inc. (NASDAQ: NTLA), a pioneer in CRISPR-based therapies, has unveiled its strategic priorities and key anticipated milestones for 2025. This announcement, made on January 9, 2025, focuses particularly on the company s late-stage programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z), marking a pivotal moment in its quest to revolutionize healthcare for patients globally.The firm s renewed focus on these advanced programs reflects an understanding of the pressing needs within the healthcare landscape, where innovative therapies can significantly alter the treatment paradigm for various diseases. By prioritizing NTLA-2002, an investigational therapy for hereditary angioedema targeting the production of bradykinin, and Nexiguran Ziclumeran (nex-z), a novel treatment for patients suffering from acute pain, Intellia aims to lead the charge in providing effective and transformative solutions.



Other Ratios
Intellia Therapeutics Inc 's Income per Employee
Employees in In Vitro & In Vivo Diagnostic Substances
In Vitro & In Vivo Diagnostic Substances Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
NTLA's Revenue per Employee versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for NTLA's Competitors
Revenue per Employee for NTLA's Suppliers
Revenue per Employee for NTLA's Customers

You may also want to know
NTLA's Sales Growth Rates NTLA's Pe Price to earnings ratio NTLA's Receivables Turnover Ratio NTLA's Stock Quote
NTLA's Net Income Growth Rates NTLA's Ps Price to Sales ratio NTLA's Sales per Employee NTLA's Asset Turnover Ratio
NTLA's Net Margin NTLA's Pb Price to Book ratio NTLA's Financial Strength Ratios NTLA's Dividend Payout Ratio
Date modified: 2026-11-09T18:44:23+00:00




Companies with similar Revenue per Employee for 12 months ending Sep 30 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Sep 30 2026Number of Employees Sep 30 2026
Fulgent Genetics Inc   245,441.22 $ 329.873  Million 1,344 
Tenet Healthcare Corp  223,777.78 $ 22,154.000  Million 99,000 
Merit Medical Systems Inc  214,964.80 $ 1,612.236  Million 7,500 
Standard Biotools Inc   214,889.46 $ 83.592  Million 389 
Labcorp Holdings Inc   208,492.86 $ 14,594.500  Million 70,000 
Quest Diagnostics Inc  207,736.84 $ 11,841.000  Million 57,000 
Pacific Health Care Organization Inc  205,413.39 $ 6.368  Million 31 
Cytomx Therapeutics Inc   203,289.86 $ 14.027  Million 69 
Fortrea Holdings Inc   186,482.52 $ 2,666.700  Million 14,300 
Abeona Therapeutics Inc   185,451.33 $ 41.912  Million 226 
Iqvia Holdings Inc   182,221.05 $ 17,311.000  Million 95,000 
Davita Inc   181,635.19 $ 14,167.545  Million 78,000 
Voyager Therapeutics Inc   178,070.92 $ 25.108  Million 141 
Chemed Corporation  168,303.14 $ 2,661.041  Million 15,811 
Icu Medical Inc  167,965.85 $ 2,183.556  Million 13,000 
Stoke Therapeutics Inc   165,947.06 $ 28.211  Million 170 
Integer Holdings Corporation  165,920.18 $ 1,825.122  Million 11,000 
Lifestance Health Group Inc   152,986.86 $ 1,676.889  Million 10,961 
Encompass Health Corporation  150,907.14 $ 6,338.100  Million 42,000 
Profound Medical Corp   145,845.68 $ 23.627  Million 162 
Intellia Therapeutics Inc   140,283.82 $ 52.887  Million 377 
Crispr Therapeutics Ag  125,233.83 $ 25.172  Million 201 
Sonida Senior Living Inc   124,149.81 $ 638.130  Million 5,140 
Ensign Group Inc  123,354.46 $ 5,674.305  Million 46,000 
Abcellera Biologics Inc   120,743.77 $ 67.858  Million 562 
Pacs Group Inc   120,220.19 $ 5,705.049  Million 47,455 
U S Physical Therapy Inc  114,838.09 $ 837.629  Million 7,294 
Recursion Pharmaceuticals Inc   113,720.00 $ 68.232  Million 600 
Amarin Corp Plcuk  107,035.76 $ 176.609  Million 1,650 
Aclaris Therapeutics Inc   87,684.93 $ 6.401  Million 73 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.